News | February 17, 2025
Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Offers affordable, high-quality solutions for diabetes care
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Subscribe To Our Newsletter & Stay Updated
